Related Experiment Video

Updated: May 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

[Metabolic impact of androgen deprivation therapy for prostate cancer]

E Andrès1, P Eschwege, H Lang

  • 1Service Médecine Interne, Diabète et Maladies métaboliques, Clinique Médicale B, CHRU Strasbourg, Strasbourg, F-67000, France. emmanuel.andres@chru-strasbourg.fr

Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie
|October 27, 2012
PubMed

Insights

Androgen deprivation therapy for prostate cancer can cause metabolic disorders like diabetes and dyslipidemia. A new questionnaire and expert recommendations aim to improve screening and management of these side effects.

Area of Science:

  • Oncology
  • Endocrinology
  • Metabolic Disorders

Context:

  • Prostate cancer treatments, particularly androgen deprivation therapy (ADT), are associated with significant long-term adverse effects.
  • Metabolic disorders such as weight gain, insulin resistance, diabetes, and dyslipidemia are common in men over 60 and exacerbated by ADT.
  • Current lack of consensus guidelines for managing metabolic disorders in prostate cancer patients.

Purpose:

  • To report the development of a new questionnaire for systematic management of metabolic disorders in prostate cancer patients.
  • To provide expert recommendations for screening and managing ADT-induced metabolic disorders.
  • To address the need for early detection and intervention of metabolic complications.

Summary:

  • A novel questionnaire has been developed to aid in the systematic management, screening, and prevention of metabolic disorders in prostate cancer patients undergoing ADT.
  • French expert board recommendations include systematic screening for diabetes, regular monitoring of glucose, lipids, and blood pressure.
  • Lifestyle modifications, including exercise and nutritional guidance, are emphasized for patients on long-term ADT.

Impact:

  • Aims to improve the quality of life for prostate cancer patients by proactively managing treatment side effects.
  • Potential to reduce the incidence and severity of metabolic disorders associated with ADT.
  • Contributes to a more comprehensive and patient-centered approach to prostate cancer care, addressing both cancer and its treatment complications.

More Related Videos

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...